Month: June 2023

Integrated eCOA & ePRO Solution Taps Company’s Decentralized Capabilities and Technology Expertise MORRISVILLE, N.C., June 26, 2023 (GLOBE NEWSWIRE) — Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with uMotif, a clinical trial technology company putting the patient at the center of research. The collaboration will help accelerate clinical trials and bring new therapies to patients faster through a more efficient, end-to-end digital platform that includes robust Electronic Clinical Outcome Assessment (eCOA) and Electronic Patient-reported Outcomes (ePRO) capabilities. In addition to uMotif providing eCOA and ePRO services for Syneos Health customers, the companies will develop and deploy an exclusive patient-centric platform to deliver...

All amounts shown in this press release are in U.S. dollars unless otherwise indicated. WINNIPEG, Manitoba, June 26, 2023 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF, TSX: NFI.DB, TSX: NFI.R) NFI Group Inc. (the “Company”), a leader in zero-emission electric mobility solutions, today provided an update on the expected timing to complete its previously announced comprehensive refinancing plan (the “Refinancing Plan”). NFI expects to concurrently complete all elements of its Refinancing Plan prior to the release of its second quarter financial results on Wednesday, August 2, 2023. To support this expected timing, NFI has received an extension of the date for the completion of the required amendments and the financial covenant waivers under the Company’s existing North American senior secured credit facility (the “North American Facility”)...

In the first cohort of the ongoing Phase 1/2 clinical trial, the first 5 patients to complete protocol-defined islet transplants achieved insulin-independence for ongoing periods of 6 to 38 months. Following islet transplants to the 8-channel Cell Pouches, patients in the first cohort required only modest islet top-up via portal vein to achieve insulin independence, supporting the contribution to blood glucose control from islet grafts in the Cell Pouch™. Five of the 7 planned patients have been enrolled in the second cohort and implanted with higher capacity 10-channel Cell Pouches. Three patients in the second cohort have received their first pancreatic islet transplant to Cell Pouch. Persistent fasting and stimulated serum C-peptide confirms stable islet graft function in the first evaluable patient to receive islet transplants...

VANCOUVER, British Columbia, June 26, 2023 (GLOBE NEWSWIRE) — Interfield Global Software Inc. (NEO: IFSS) (the “Company”) is pleased to announce that Interfield Software Solutions LLC, the Software as a Service division of the Company (“Interfield”), has signed a co-marketing agreement with AARO Middle East DMCC (“AARO”). AARO is part of AARO Systems AB Sweden and is in the business of accounting software services, executive recruitment and event management. In furtherance of the agreement, Interfield will be a partner of the 2023 Finex Summit, a global virtual summit on September 13, 2023 targeted at the continuing personal development of Global Finance Leaders. This annual summit is managed by AARO Middle East and CFO University (www.finexsummit.com). For over 30 years, AARO been implementing technology-based accounting...

POINT’s vertically integrated platform together with AdvanCell’s lead-212 (²¹²Pb) generator technology enables both the development and scaled commercialization of ²¹²Pb-labeled radioligand therapies INDIANAPOLIS and SYDNEY, Australia, June 26, 2023 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, and AdvanCell, a company developing an innovative pipeline of targeted alpha therapies with a platform technology to produce 212Pb radiopharmaceuticals, today announced a collaboration on the development of a global 212Pb radioisotope and radioligand supply chain and drug manufacturing network to specifically support the clinical development and commercialization of 212Pb-labeled radioligands...

WORCESTER, Mass., June 26, 2023 (GLOBE NEWSWIRE) — Mass Megawatts Wind Power, Inc. (OTC:MMMW) www.massmegawatts.com today announces that the Company has nearly completed the process of changing the name of the Company from Mass Megawatts Wind Power, Inc. to Mass Megawatts, Inc. The Company will announce the date of the name change as soon as the Company completes the regulatory process. The CUSIP number and stock ticker symbol will remain the same. Since most of our business has been involved with solar energy related activity since 2014, we believe that changing our name from Mass Megawatts Wind Power, Inc. to Mass Megawatts, Inc. is a reasonable action to reflect the business of the Company more accurately in recent years. At the same time, the Company will continue with wind power activities while most of our business will be...

The Annual General Meeting of Awilco Drilling PLC was held Monday 26 June 2023 at 12:00 noon (UK time), at the offices of Awilco Drilling on 2 Kingshill Park, Venture Drive, Arnhall Business Park, Westhill, Aberdeen, AB32 6FL, UK. Each of the resolutions set out in the Meeting Notice were duly passed. The signed minutes of meeting are attached hereto. The Meeting Notice and Appendices are available on our website www.awilcodrilling.com, under ‘Investor Relations/General Meetings’. Aberdeen, 26 June 2023 For further information please contact: Eric Jacobs, Interim CEOPhone: +44 1224 737900 Cathrine Haavind, Investor RelationsPhone: +47 93 42 84 64Email: ch@awilcodrilling.com This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.      AttachmentAWDR AGM...

– Study’s Primary Efficacy Endpoint Achieved, with 46.2% of Patients in the 50 mg BID Mitapivat Arm and 50.0% of Patients in the 100 mg BID Mitapivat Arm Achieving a Hemoglobin Response, Compared to 3.7% of Patients in the Placebo Arm – – A Trend in Sickle Cell Pain Crisis Reduction was Observed in Both Mitapivat Dose Arms Compared to Placebo – – Company Expects to Enroll First Patient in Phase 3 Portion of Study in Q4 2023, Report Phase 3 Data in 2025 and Potentially Receive U.S. Approval in 2026 – – Agios to Host Investor Webcast Event Today at 8:00 a.m. ET – CAMBRIDGE, Mass., June 26, 2023 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the Phase 2 portion of the global RISE UP study of mitapivat in sickle...

Strategic collaboration signed to support the development of radiopharmaceuticals in the fight against cancer Chicago, IL, USA, June 26, 2023: TerraPower Isotopes and PanTera, the Belgian joint venture created by SCK CEN and IBA, announced today that they have signed a strategic collaboration to increase the global availability of actinium-225 (225Ac), a radioisotope that has the potential to treat a large variety of cancer indications. The companies will work together to increase near-term production of 225Ac1 to support ongoing clinical trials and to ensure the large-scale supply of the radioisotope in the long term, addressing growing global demand. This collaboration will not have any immediate financial impact but has the potential to bring substantial revenues in the future to PanTera and, indirectly, to its two shareholders SCK...